HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer: Analysis of second-line treatment after anti-EGFR antibody

被引：0

作者：

Yoshikawa, A. ^{[1
]}

Ito, K. ^{[2
]}

Yuki, S. ^{[3
]}

Kawamoto, Y. ^{[2
]}

Saito, R. ^{[2
]}

Yamamura, T. ^{[3
]}

Yagisawa, M. ^{[4
]}

Ishiguro, A. ^{[5
]}

Muto, O. ^{[6
]}

Hatanaka, K. ^{[7
]}

Okuda, H. ^{[8
]}

Sato, A. ^{[9
]}

Sasaki, Y. ^{[10
]}

Nakamura, M. ^{[11
]}

Sasaki, T. ^{[12
]}

Kobayashi, T. ^{[13
]}

Dazai, M. ^{[14
]}

Nakatsumi, H. ^{[15
]}

Ueda, A. ^{[16
]}

Sakata, Y. ^{[17
]}

Komatsu, Y. ^{[2
]}

机构：

[1] Kushiro Rosai Hosp, Dept Med Oncol, Kushiro, Japan

[2] Hokkaido Univ Hosp, Div Canc Ctr, Sapporo, Hokkaido, Japan

[3] Hokkaido Univ Hosp, Dept Gastroenterol & Hepatol, Sapporo, Hokkaido, Japan

[4] Japanese Red Cross Kitami Hosp, Dept Med Oncol, Kitami, Hokkaido, Japan

[5] Teine Keijinkai Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[6] Japanese Red Cross Akita Hosp, Dept Med Oncol, Akita, Japan

[7] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido, Japan

[8] Keiyukai Sapporo Hosp, Dept Med Oncol, Sapporo, Hokkaido, Japan

[9] Hirosaki Univ, Grad Sch Med, Dept Med Oncol, Hirosaki, Aomori, Japan

[10] Hakodate Cent Gen Hosp, Dept Med Oncol, Hakodate, Hokkaido, Japan

[11] Sapporo City Gen Hosp, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[12] Hokkaido Gastroenterol Hosp, Dept Internal Med, Sapporo, Hokkaido, Japan

[13] Tomakomai City Hosp, Dept Gastroenterol, Tomakomai, Japan

[14] Sapporo Med Ctr NTT EC, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[15] Hokkaido Med Ctr, Dept Gastroenterol, Sapporo, Hokkaido, Japan

[16] Toyama Red Cross Hosp, Dept Med Oncol, Toyama, Japan

[17] Misawa City Hosp, Misawa, Japan

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.05.134

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-79

引用

页码：S124 / S124

页数：1

共 50 条

[11] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
Suenaga, Mitsukuni
Matsusaka, Satoshi
Ueno, Masashi
Yamamoto, Noriko
Shinozaki, Eiji
Mizunuma, Nobuyuki
Yamaguchi, Toshiharu
Hatake, Kiyohiko
[J]. SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
[12] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
Toshi Takaoka
Tetsuo Kimura
Rai Shimoyama
Shunji Kawamoto
Kazuki Sakamoto
Fuminori Goda
Hiroshi Miyamoto
Yuji Negoro
Akihito Tsuji
Koji Yoshizaki
Takahiro Goji
Shinji Kitamura
Hiromi Yano
Koichi Okamoto
Masako Kimura
Toshiya Okahisa
Naoki Muguruma
Yoshiro Niitsu
Tetsuji Takayama
[J]. Cancer Chemotherapy and Pharmacology, 2016, 78 : 397 - 403
[13] Panitumumab in combination with irinotecan plus S-1 (IRIS) as second-line therapy for metastatic colorectal cancer
Takaoka, Toshi
Kimura, Tetsuo
Shimoyama, Rai
Kawamoto, Shunji
Sakamoto, Kazuki
Goda, Fuminori
Miyamoto, Hiroshi
Negoro, Yuji
Tsuji, Akihito
Yoshizaki, Koji
Goji, Takahiro
Kitamura, Shinji
Yano, Hiromi
Okamoto, Koichi
Kimura, Masako
Okahisa, Toshiya
Muguruma, Naoki
Niitsu, Yoshiro
Takayama, Tetsuji
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 397 - 403
[14] Retrospective Cohort Study on the Safety and Efficacy of Bevacizumab with Chemotherapy for Metastatic Colorectal Cancer Patients: The HGCSG0801 Study
Sogabe, Susumu
Komatsu, Yoshito
Yuki, Satoshi
Kusumi, Takaya
Hatanaka, Kazuteru
Nakamura, Michio
Kato, Takashi
Miyagishima, Takuto
Hosokawa, Ayumu
Iwanaga, Ichiro
Sakata, Yuh
Asaka, Masahiro
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (04) : 490 - 497
[15] Retrospective cohort study on the safety and efficacy of bevacizumab for metastatic colorectal cancer patients: The HGCSG0801study-Analysis of bevacizumab beyond progression (BBP).
Fukushima, Hiraku
Yuki, Satoshi
Kobayashi, Yoshimitsu
Hatanaka, Kazuteru
Kusumi, Takaya
Hosokawa, Ayumu
Miyagishima, Takuto
Takeuchi, Satoshi
Kudo, Mineo
Komatsu, Yoshito
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
[16] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
Hitoshi Kusaba
Taito Esaki
Junji Kishimoto
Keita Uchino
Shuji Arita
Hozumi Kumagai
Kenji Mitsugi
Koichi Akashi
Eishi Baba
[J]. Cancer Chemotherapy and Pharmacology, 2013, 71 : 29 - 34
[17] Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer
Kusaba, Hitoshi
Esaki, Taito
Kishimoto, Junji
Uchino, Keita
Arita, Shuji
Kumagai, Hozumi
Mitsugi, Kenji
Akashi, Koichi
Baba, Eishi
[J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (01) : 29 - 34
[18] Updated analysis: A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer-HGCSG1401.
Ota, Yumiko
Yuki, Satoshi
Liarada, Kazuaki
Yoshida, Shuntaro
Tsuji, Yasushi
Kobayashi, Yoshimitsu
Hatanaka, Kazuteru
Okuda, Hiroyuki
Sasaki, Takahide
Dazai, Masayoshi
Konno, Jun
Ohta, Tomoyuki
Honda, Takuya
Ishiguro, Atsushi
Muto, Osamu
Sato, Yasushi
Kato, Sosuke
Onodera, Kei
Sakata, Yuh
Komatsu, Yoshito
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
[19] Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies
Nakatsumi, Hiroshi
Komatsu, Yoshito
Muranaka, Tetsuhito
Yuki, Satoshi
Kawamoto, Yasuyuki
Harada, Kazuaki
Dazai, Masayoshi
Tateyama, Miki
Sasaki, Yusuke
Miyagishima, Takuto
Tsuji, Yasushi
Katagiri, Masaki
Nakamura, Michio
Sogabe, Susumu
Hatanaka, Kazuteru
Meguro, Takashi
Kobayashi, Tomoe
Ishiguro, Atsushi
Muto, Osamu
Shindo, Yoshiaki
Kotaka, Masahito
Ando, Takayuki
Takagi, Ryo
Sakamoto, Naoya
Sakata, Yu
[J]. FRONTIERS IN ONCOLOGY, 2022, 12
[20] A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy for colorectal cancer: The AIRS study
Honda, M.
Matsuda, C.
Tanaka, C.
Kondo, K.
Takahashi, T.
Kosugi, C.
Tokunaga, Y.
Takemoto, H.
Kim, H. M.
Sakamoto, J.
Oba, K.
Mishima, H.
[J]. ANNALS OF ONCOLOGY, 2018, 29 : 161 - 161

← 1 2 3 4 5 →